CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial. (2017)

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s1470-2045(17)30434-5

PubMed Identifier: 28592386

Publication URI: http://europepmc.org/abstract/MED/28592386

Type: Journal Article/Review

Volume: 18

Parent Publication: The Lancet. Oncology

Issue: 7

ISSN: 1470-2045